1. Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome 
Claudia I. Reinders, Max Herulf, Tryggve Ljung, Jakob Hollenberg, Eddie Weitzberg, Jon O. Lundberg, Per M. Hellström 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 8, Pages (August 2005)
DOI: /S (05)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Rectal NO levels in healthy subjects (controls), patients with IBS, active Crohn’s disease (CD), active ulcerative colitis (UC), and active collagenous colitis (CC). The horizontal lines show the median for each group. The dotted line represents a cutoff value for rectal NO at 250 ppb.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Rectal NO levels in IBD (Crohn’s disease and ulcerative colitis) patients with different disease activity.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Receiveroperating characteristics analysis of the ability of rectal NO levels to discriminate between patients with active bowel inflammation (Crohn’s disease, ulcerative colitis, and collagenous colitis) and IBS. A cutoff value of 250 ppb for rectal NO levels gives a sensitivity and specificity of 95% and 91%, respectively.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
Individual rectal NO levels in healthy subjects measured repeatedly during a 2-week period.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

6. Figure 5
Rectal NO levels in patients with active ulcerative colitis measured before and after 4 weeks of medical treatment. NO levels decreased significantly (**P < 0.01) only in patients responding to therapy with complete remission.
Clinical Gastroenterology and Hepatology 2005 3, DOI: ( /S (05) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions